#Serological Testing Market Report | Explore Tumblr posts and blogs

taniyaaskd · 24 days ago

Text

Tularemia Infection Market Research Report: Growth, Share, Value, Size, and Insights

"Tularemia Infection Market Size And Forecast by 2032

The Tularemia Infection Market is a rapidly expanding industry that plays a critical role in shaping global economic dynamics. With its remarkable size, share, and scope, the market has become a focal point for innovation, investment, and growth. This comprehensive research report delves into the market's evolution, offering insights into its current performance and future outlook. It examines key factors such as demand, growth drivers, and revenue trends that are shaping the industry's trajectory.

The global tularemia infection market size was valued at USD 48.13 billion in 2024 and is projected to reach USD 104.22 billion by 2032, with a CAGR of 10.14% during the forecast period of 2025 to 2032.

Get a Sample PDF of Report - https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-tularemia-infection-market

Which are the top companies operating in the Tularemia Infection Market?

The Top 10 Companies in Tularemia Infection Market are prominent players known for their leadership and innovation. These include companies recognized for their strong product offerings and market influence. These companies have built solid reputations through their commitment to quality, customer satisfaction, and staying ahead of industry trends, making them key competitors in the Tularemia Infection Market.

**Segments**

- **By Type**: The global tularemia infection market can be segmented into ulceroglandular tularemia, glandular tularemia, oculoglandular tularemia, oropharyngeal tularemia, pneumonic tularemia, and typhoidal tularemia. Each type presents varying symptoms and severity levels, impacting the overall treatment and management strategies.

- **By Diagnosis**: Diagnosis segments include laboratory testing (culture, PCR, serology), imaging tests (X-rays, CT scans), and physical examination. Accurate and timely diagnosis is crucial for effective treatment and preventing the spread of tularemia infection.

- **By Treatment**: Treatment options for tularemia infection encompass antibiotics such as streptomycin, gentamicin, doxycycline, and ciprofloxacin. The choice of treatment depends on the type and severity of tularemia, as well as patient-specific factors.

**Market Players**

- **GlaxoSmithKline plc**: A leading pharmaceutical company involved in the development and commercialization of vaccines and antibiotics for various infectious diseases, including tularemia infection.

- **Bayer AG**: Known for its extensive portfolio of healthcare products, Bayer AG plays a significant role in providing treatment options for tularemia infection globally.

- **Pfizer Inc.**: Pfizer is a key player in the global pharmaceutical industry, focusing on research, development, and marketing of medications for infectious diseases like tularemia.

- **Merck & Co., Inc.**: Merck is a prominent player in the healthcare sector, offering innovative solutions for tularemia infection through its range of pharmaceutical products.

- **Johnson & Johnson Services, Inc.**: With a strong presence in the healthcare market, Johnson & Johnson is actively engaged in developing therapies and vaccines for tularemia and other infectious diseases.

The global tularemia infection market is witnessing significant growth due to the increasing prevalence of tularemia cases worldwide. Key market players are investing in research and development activities to introduce advanced diagnostic tools and treatment options for better patient outcomes. Improved healthcare infrastructure and rising awareness about tularemia infection are also driving market expansion. Collaboration among pharmaceutical companies, healthcare providers, and regulatory bodies is essential to address the challenges associated with tularemia infection and enhance overall market growth.

https://www.databridgemarketresearch.com/reports/global-tularemia-infection-marketThe global tularemia infection market is poised for substantial growth in the coming years as it continues to attract the attention of key market players and stakeholders. One notable trend in the market is the increasing focus on personalized medicine and precision healthcare for managing tularemia infections. With advancements in medical technology and understanding of the disease pathology, there is a growing emphasis on developing targeted therapies tailored to individual patient profiles. This approach not only enhances treatment efficacy but also minimizes potential side effects of broad-spectrum antibiotics traditionally used for tularemia.

Moreover, the market is witnessing a surge in strategic collaborations and partnerships between pharmaceutical companies, research institutions, and government agencies to expedite the development of novel diagnostics and therapeutics for tularemia infection. By pooling resources and expertise, these stakeholders are leveraging synergies to overcome the complex challenges posed by tularemia and deliver innovative solutions to healthcare providers and patients. This collaborative spirit is crucial for driving innovation in the market and addressing unmet medical needs associated with tularemia.

Another key driver of market growth is the rising public health awareness regarding tularemia infection and its potential consequences. Governments and healthcare organizations across the globe are intensifying efforts to educate the public about the risk factors, transmission pathways, and preventive measures related to tularemia. By promoting early detection and prompt treatment, these initiatives aim to reduce the incidence of tularemia cases and improve patient outcomes. This proactive approach not only benefits individual patients but also contributes to the overall containment of tularemia outbreaks and outbreaks.

Furthermore, the increasing investments in research and development activities dedicated to tularemia infection are shaping the future trajectory of the market. Market players are exploring innovative therapeutic modalities, such as immunotherapies and gene editing technologies, to augment the existing armamentarium of antibiotics for tularemia treatment. These novel approaches hold the potential to revolutionize the standard of care for tularemia patients and pave the way for more efficacious and targeted interventions in the years to come.

In conclusion, the global tularemia infection market is undergoing a dynamic transformation characterized by advancements in personalized medicine, collaborative research efforts, heightened public health awareness, and ongoing innovation in therapeutics. As the market continues to evolve, stakeholders must remain vigilant to emerging trends and opportunities that can drive sustainable growth and improve patient outcomes in the fight against tularemia infection.**Segments**

Global Tularemia Infection Market Segmentation includes varying types such as Ulceroglandular, Typhoidal, Oculoglandular, and others, each with distinct symptoms and severity levels impacting treatment approaches. Treatment options range from medication, vaccinations, to surgery, with antibiotics like aminoglycosides, quinolones, and other drug classes used. Vaccines for tularemia infection consist of live attenuated vaccines, acellular subunit options, and others. Administration routes include oral and injectable methods, catering to different patient needs. Various end users such as hospitals, homecare settings, specialty clinics, among others, are pivotal in delivering care. Distribution channels encompass hospital pharmacies, retail pharmacies, and others, ensuring efficient dissemination of treatment options.

**Market Players**

- Appili Therapeutics (Canada) - Merck & Co., Inc (U.S.) - Debiopharm (Switzerland) - EpiVax, Inc. (U.S.) - Cerus Corporation (U.S.) - EMERGENT (U.S.) - Sun Pharmaceutical Industries Ltd (India) - Fresenius Kabi AG (Germany) - Teva Pharmaceutical Industries Ltd (Israel) - Novartis AG (Switzerland) - Pfizer Inc (U.S.) - Eli Lilly and Company (U.S.) - Viatris Inc. (U.S.) - Zydus Group (India) - Bayer AG (Germany) - AbbVie Inc (U.S.)

The global tularemia infection market is witnessing a significant growth trend driven by various factors such as increasing prevalence worldwide, advancements in treatment modalities, and robust investments in research and development by key market players. The market segmentation based on type, diagnosis, and treatment options allows for a tailored approach in managing tularemia infections, leading to better patient outcomes. Collaborative efforts among pharmaceutical companies, healthcare providers, and regulatory bodies are essential to address the challenges associated with tularemia and facilitate market expansion.

Key market players such as Merck & Co., Inc., Pfizer Inc., and Bayer AG, among others, play a crucial role in driving innovation and offering a diverse range of treatment options for tularemia infection. With a focus on personalized medicine and precision healthcare, the market is evolving towards individualized therapies to optimize patient care and minimize adverse effects. Strategic collaborations and partnerships are also on the rise, fostering research initiatives and accelerating the development of novel diagnostics and therapeutics for tularemia.

Moreover, the increasing public health awareness and proactive initiatives by governments and healthcare organizations are contributing to the early detection and containment of tularemia outbreaks. Investment in research and development activities geared towards exploring novel therapeutic modalities like immunotherapies and gene editing technologies is reshaping the future landscape of tularemia treatment. This ongoing innovation and collaborative spirit within the market are poised to drive sustainable growth and enhance patient outcomes in combating tularemia infections in the years to come.

Explore Further Details about This Research Tularemia Infection Market Report https://www.databridgemarketresearch.com/reports/global-tularemia-infection-market

Key Insights from the Global Tularemia Infection Market :

Comprehensive Market Overview: The Tularemia Infection Market is experiencing robust growth driven by technological advancements and increasing consumer demand.

Industry Trends and Projections: The market is projected to expand at a CAGR of X% over the next five years, with a significant shift towards sustainability.

Emerging Opportunities: Growing demand for innovative products and services presents new business opportunities in niche segments.

Focus on R&D: Companies are investing heavily in research and development to stay ahead in a competitive market landscape.

Leading Player Profiles: Key players include known for their market leadership and innovation.

Market Composition: The market is fragmented, with both large corporations and small enterprises playing vital roles.

Revenue Growth: The market has seen a steady increase in revenue, driven by strong consumer adoption and product diversification.

Commercial Opportunities: Businesses can capitalize on untapped regional markets and technological advancements to gain a competitive edge.

Find Country based languages on reports:

https://www.databridgemarketresearch.com/jp/reports/global-tularemia-infection-markethttps://www.databridgemarketresearch.com/zh/reports/global-tularemia-infection-markethttps://www.databridgemarketresearch.com/ar/reports/global-tularemia-infection-markethttps://www.databridgemarketresearch.com/pt/reports/global-tularemia-infection-markethttps://www.databridgemarketresearch.com/de/reports/global-tularemia-infection-markethttps://www.databridgemarketresearch.com/fr/reports/global-tularemia-infection-markethttps://www.databridgemarketresearch.com/es/reports/global-tularemia-infection-markethttps://www.databridgemarketresearch.com/ko/reports/global-tularemia-infection-markethttps://www.databridgemarketresearch.com/ru/reports/global-tularemia-infection-market

Data Bridge Market Research:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC: +653 1251 975

Email:- [email protected]"

0 notes

sometimespurvi · 26 days ago

Text

Global HLA Typing Market: Growth Trends, Technologies, and Future Outlook

Market Overview

The global HLA typing market has experienced significant growth over the years, with an estimated market size of $33.4 billion in 2023. Projections indicate a remarkable expansion to $562.97 million by 2031, growing at a CAGR of 36.4% from 2024 to 2031. This rapid growth is fueled by increasing organ transplantation procedures, advancements in genetic testing, and the rising prevalence of autoimmune diseases.

Browse More : https://www.statsandresearch.com/report/40445-global-hla-typing-market/

Understanding HLA Typing

HLA typing is a laboratory test used to identify specific human leukocyte antigen (HLA) markers on an individual's cells. These markers are crucial for immune system function, helping distinguish self from non-self. The process is essential in organ transplantation to reduce the risk of rejection, as well as in autoimmune disease diagnosis and research. Accurate HLA typing ensures compatibility in transplantation, leading to improved patient outcomes.

Get a free sample copy : https://www.statsandresearch.com/request-sample/40445-global-hla-typing-market

Market Segmentation

By Geography

The HLA typing market is analyzed across multiple regions, including:

North America (United States, Canada)

Asia-Pacific (China, Japan, India, Korea, ASEAN)

Europe (Germany, France, UK, Italy, Spain, CIS)

Middle East and Africa

South America (Brazil and other key nations) Each region exhibits unique market dynamics, with North America leading in adoption due to advanced healthcare infrastructure and research capabilities.

By Technology

HLA typing employs various technological approaches, broadly classified into:

Molecular Assays:

Polymerase Chain Reaction (PCR): Identifies specific HLA alleles using amplification techniques.

Sequence-Specific Oligonucleotide (SSO) Probes: Detects genetic variations in HLA genes.

Sequence-Specific Primer (SSP) Typing: Provides high-precision allele identification.

Real-Time PCR (qPCR): Offers quantitative analysis of allele expression.

Next-Generation Sequencing (NGS): Enables high-resolution typing by sequencing entire HLA genes.

Sanger Sequencing: Provides accurate validation for identified HLA genes.

Non-Molecular Assays:

Serological Assays: Detect HLA antigens through antibody-based techniques.

Mixed Lymphocyte Culture (MLC): Assesses immune compatibility by analyzing lymphocyte responses.

By Product & Service

HLA typing solutions are categorized into:

Instruments: Sequencers, PCR systems

Reagents & Consumables: Oligonucleotide probes, antibodies, assay kits

Software & Services: HLA typing software, data analysis services, consulting services

By Application

Transplantation:

Solid Organ Transplantation (Kidney, Liver, Heart)

Hematopoietic Stem Cell Transplantation (HSCT)

Disease Diagnosis:

Cancer

Autoimmune Diseases

Infectious Diseases

Research:

Immunogenetics

Population Genetics

By End User

Hospitals & Transplant Centers

Academic & Research Institutes

Diagnostic Laboratories

Pharmaceutical & Biotechnology Companies

Enquiry : https://www.statsandresearch.com/enquire-before/40445-global-hla-typing-market

Key Market Players

The competitive landscape comprises leading biotechnology and diagnostics companies, including:

Thermo Fisher Scientific Inc.

Bio-Rad Laboratories Inc.

Qiagen N.V.

Omixon Inc.

GenDx

Illumina Inc.

TBG Diagnostics Limited

Dickinson and Company

Takara Bio Inc.

F. Hoffman-La Roche Limited

Pacific Biosciences

Future Outlook

The HLA typing market is poised for continued expansion, driven by technological advancements, increased healthcare investments, and the growing demand for precision medicine. As the industry evolves, improved sequencing techniques and AI-driven data analysis will further enhance HLA typing accuracy and efficiency, solidifying its role in transplantation and disease management.

For customized insights or sample pages of this report, feel free to reach out!

Find Out Top Trending Reports Here :

Global Sex Reassignment Surgery Market

Global Enzyme Engineering Market

Global Neuroelectronic Devices Market

Global Vitamin K2 Market Insights

Global Defibrillator Market Insights

0 notes

kkumarsblog · 1 month ago

Text

Exploring the Gluten Sensitivity Market: Growth Opportunities, Challenges, and Innovations

The rising awareness of gluten-related health issues has led to increased attention on non-celiac gluten sensitivity (NCGS). This condition affects a broad segment of the population, triggering symptoms similar to celiac disease but without the associated intestinal damage. DelveInsight’s latest report offers a comprehensive analysis of market trends, leading industry players, and future growth prospects. With more people being diagnosed, the market is on a trajectory of rapid expansion, encouraging new research, enhanced diagnostic capabilities, and innovative treatment solutions.

Understanding Gluten Sensitivity Therapeutics Market

Gluten sensitivity is characterized by symptoms such as bloating, abdominal pain, fatigue, headaches, and joint discomfort following gluten consumption. Unlike celiac disease, NCGS does not cause intestinal damage or trigger specific antibodies, making diagnosis a challenge.

The global prevalence of gluten sensitivity is increasing due to greater awareness, lifestyle shifts, and improvements in diagnostic techniques. This growth has fueled demand for gluten-free products, medical diagnostics, and therapeutic solutions.

Key Market Drivers

1. Prevalence and Epidemiology

Gluten sensitivity is estimated to affect 0.5% to 6% of the global population, making it a notable public health issue. The increase in self-reported cases, coupled with advances in diagnostic methods, is driving market expansion.

2. Rising Demand for Gluten-Free Products

The gluten-free food industry has seen substantial growth, fueled by both medical necessity and consumer preference. While those with celiac disease must strictly avoid gluten, many gluten-sensitive individuals—and even some without gluten-related conditions—are adopting gluten-free diets. This demand has driven innovation in gluten-free food production, resulting in better-quality alternatives.

3. Advancements in Diagnostic Technologies

Accurate diagnosis remains a significant challenge in gluten sensitivity. Unlike celiac disease, which can be confirmed through serological tests and biopsies, gluten sensitivity lacks definitive biomarkers. This gap has led to a surge in research efforts focused on non-invasive diagnostic solutions that could significantly enhance patient care. Companies investing in such cutting-edge diagnostic technologies stand to gain a strong market advantage.

4. Emerging Therapeutic Innovations

Currently, the only treatment for gluten sensitivity is adhering to a gluten-free diet. However, research is underway to develop adjunct therapies, such as:

Enzyme-based solutions to help break down gluten.Probiotics and gut microbiome modulators to support digestion.Immune-modulating therapies to enhance gluten tolerance.

These emerging treatments represent a new and untapped segment within the market, with the potential to transform patient care.

Key Gluten Sensitivity Companies and Innovations

The gluten sensitivity market is shaped by food manufacturers, diagnostic firms, and pharmaceutical developers. Prominent players include:

Nestlé Health Science – Developing dietary solutions for gluten-related disorders.Schar – A leading provider of gluten-free food products.Provention Bio – Focused on immune-modulating therapies for gluten intolerance.Innovate Biopharmaceuticals – Researching treatment options for celiac disease and gluten sensitivity.

These companies are actively engaged in research, innovation, and strategic partnerships, ensuring the market remains competitive and dynamic.

Regional Market Insights1. North America

North America dominates the gluten sensitivity market, thanks to high awareness levels, advanced healthcare infrastructure, and a strong gluten-free food industry. The United States leads the region, with increasing diagnoses and widespread availability of gluten-free products.

2. Europe

Europe has experienced a rise in gluten sensitivity cases due to improved diagnostic techniques and heightened public awareness. Key markets such as the United Kingdom, Germany, and Italy benefit from strong regulatory frameworks governing gluten-free food labeling and quality standards.

3. Asia-Pacific

The Asia-Pacific region is witnessing rapid growth in the gluten sensitivity market, driven by urbanization, dietary changes, and increasing healthcare investments. While awareness is still developing, the market holds significant expansion potential.

4. Rest of the World

Emerging markets in Latin America, the Middle East, and Africa are gradually acknowledging the importance of gluten-related disorders. Increased healthcare accessibility and educational initiatives are expected to drive future market growth in these regions.

Challenges in the Gluten Sensitivity Market

Despite its growth potential, the market faces several key challenges:

Lack of Standardized Diagnostics – The absence of definitive biomarkers makes diagnosis difficult, leading to misdiagnosis and delayed treatment.Dietary Compliance Issues – Maintaining a gluten-free diet is challenging, especially in areas with limited or expensive gluten-free options.Public Misconceptions – Gluten sensitivity is often misunderstood as merely a dietary choice, impacting research funding and public perception.Regulatory Barriers – Inconsistent gluten-free labeling standards across different regions pose challenges for manufacturers and consumers.

Addressing these challenges requires a multifaceted approach, including investment in research, public education, and improved policy frameworks.

Future Market Outlook

The gluten sensitivity market is poised for substantial expansion, driven by:

Biomarker Discovery – The identification of gluten sensitivity biomarkers could revolutionize diagnosis and treatment.Personalized Nutrition – Advances in gut microbiota research and genetic profiling are paving the way for customized dietary solutions.Technological Integration – Digital tools such as health apps and wearable devices will enhance symptom tracking, dietary management, and patient education.Expansion in Emerging Markets – Companies are focusing on underserved regions where awareness and diagnostic efforts are still evolving.

Conclusion

The gluten sensitivity market is a fast-evolving industry with significant growth potential. As awareness increases and diagnostic and therapeutic solutions improve, companies across healthcare, food, and pharmaceutical sectors are well-positioned to capitalize on emerging opportunities.

DelveInsight’s comprehensive market analysis provides in-depth insights to help industry leaders, healthcare providers, and investors make strategic decisions in this growing space. With continued research and innovation, the gluten sensitivity market is set to transform the landscape of patient care and dietary solutions.

List of Top Selling Market Research Reports in 2025

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare sectors. With a focus on providing actionable insights, DelveInsight empowers pharmaceutical, biotech, and medical device companies to make informed decisions in competitive and evolving markets.

Contact Information Kanishk [email protected]

0 notes

global-research-report · 2 months ago

Text

Comprehensive Study on the Multiplex Assay Market

The global multiplex assay market size is expected to reach USD 3.87 billion by 2030, registering a CAGR of 14.77% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of infectious diseases is boosting the usage of multiplex assays in clinical trials. For instance, according to the American Cancer Society in 2021, 1.9 million cancer cases were reported along with 6,08,570 deaths in the United States. Multiplex assay aids in the diagnosis of cancer and reduces unnecessary invasive producers. Thus, growing chronic diseases can boost the necessity of these assays and is anticipated to fuel market growth. The increasing adoption of personalized medicine in recent years is another key factor driving the growth.

Personalized medicine is a precise medicine for an individual patient to attain improved treatment options based on the body type and disease risk. These assays ensure to be highly beneficial for the comprehensive diagnosis of personalized medicines. For instance, according to an article published in the MDPI journal in 2020, multiplex immunoassay provides a complete picture of the disease and pathways involved in Rheumatoid Arthritis (RA) and simultaneously analyzes multiple proteins that can yield biomarker signatures of RA subtypes to enable patients to benefit from personalized medicine. During the COVID-19 pandemic, multiplex testing continued to be an essential tool for healthcare professionals in effectively managing the spread of COVID-19. In addition, recently, several private companies have also developed novel versions of multiplex assays.

For instance, in Sept 2020, LabCorp launched an at-home collection version for diagnosis of influenza A/B, COVID-19, and respiratory syncytial virus single-panel tests. Furthermore, the advantages of multiplex assay over singleplex and traditional assay can boost the industry growth in coming years. Several benefits offered by these automated tests include microsampling capability, numerous arrays measured in a single trial, quicker results, high operational efficiency, easy operations, and reduced labor expenses. Thus, the industry has witnessed incremental growth in 2021 and is anticipated to have a similar trend during the forecast period. Moreover, increasing validation of the biomarkers in molecular & protein diagnostics and the rising need for high-throughput and automated systems are expected to create lucrative opportunities during the forecast period.

Multiple biomarker analysis has a wide range of applications in the area of infectious diseases, neurodegenerative diseases, autoimmune diseases, and cancer. Numerous biomarkers are being discovered, and there is a high possibility of the development of novel diagnostics. For instance, Cipla launched RT Direct multiplex PCR kit that delivers quicker results for COVID-19. Such developments can increase the market penetration of multiplex assay during the forecast period. The technological advancements and automation in the multiplex assay, improve the efficiency and speed of delivering accurate results. For instance, in July 2020, Luminex provided xMAP the INTELLIFLEX system to discover novel applications, including the exclusive ability to detect multiple antibodies in a single serology test.

In May 2022, Vela Diagnostics launched a highly automated multiplex PCR-based test for detecting antimicrobial resistance genes and UTI pathogens. Hence novel technological developments can fuel the industry growth in the near future. However, the high cost of equipment can restrict the usage of multiplex assays by researchers and manufacturers in mid and low-income countries. Also, the quality control standards and regulations are more stringent for multiplex assay compared to singlex assay, which can impede the industry growth during the forecast period.

Multiplex Assay Market Report Highlights

By product, the consumables segment held the dominant share in 2022. This is due to the recurring purchase of consumables along with the rise in the number of diagnostic tests

The protein multiplex assay type segment dominated the industry in 2022 due to the increasing focus on proteomics studies for biomarker research and clinical diagnostics

The flow cytometry technology segment held a larger share in 2022. Constant efforts by various companies to launch novel and technological advanced flow cytometer is the key factor driving the segment

The research & development application segment held the largest share in 2022 due to the utilization of these assays in clinical & preclinical stages to evaluate toxicity, immunotherapy success, and drug response biomarkers

The pharmaceutical & biotechnology companies end-user segment led the industry in 2022 due to a rise in pharma & biotech partnerships and collaborations to increase the multiplexing capabilities

North America dominated the global industry in 2022 due to the growing R&D activities as a result of the increasing prevalence of chronic diseases

Asia Pacific is estimated to register the fastest CAGRfrom 2022 to 2030 due to the rising number of hospitals in emerging countries, the developing R&D sector, and the high demand for healthcare infrastructure in the region

Multiplex Assay Market Segmentation

Grand View Research has segmented the global multiplex assay market based on product, type, technology, application, end-user, and region:

Multiplex Assay Product Outlook (Revenue, USD Million, 2018 - 2030)

Consumables

Instruments

Software

Multiplex Assay Type Outlook (Revenue, USD Million, 2018 - 2030)

Protein Multiplex Assays

Planar Protein Assays

Bead-based Protein Assays

Nucleic Acid Multiplex Assays

Planar Protein Assays

Bead-based Protein Assays

Cell-based Multiplex Assays

Multiplex Assay Technology Outlook (Revenue, USD Million, 2018 - 2030)

Flow Cytometry

Fluorescence Detection

Luminescence

Multiplex Real-time PCR

Other Technologies

Multiplex Assay Application Outlook (Revenue, USD Million, 2018 - 2030)

Research & Development

Drug Discovery & Development

Biomarker Discovery & Validation

Clinical Diagnostics

Infectious Diseases

Cancer

Cardiovascular Diseases

Autoimmune Diseases

Nervous System Disorders

Metabolism & Endocrinology Disorders

Other Diseases

Multiplex Assay End-user Outlook (Revenue, USD Million, 2018 - 2030)

Pharmaceutical & Biotechnology Companies

Hospitals & Diagnostic laboratories

Research & Academic Institutes

Other End-users

Multiplex Assay Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

Canada

Europe

Germany

France

Italy

Spain

Asia Pacific

Japan

China

India

South Korea

Australia

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

South Africa

Saudi Arabia

UAE

Order a free sample PDF of the Multiplex Assay Market Intelligence Study, published by Grand View Research.

#Multiplex Assay Market

0 notes

lovelypol · 4 months ago

Text

Zika Virus Testing Market to Expand to $4.3 Billion by 2033 with a 5.8% CAGR

Zika Virus Testing Market : Zika virus testing is a critical tool in the global fight against vector-borne diseases. Accurate and timely diagnosis helps identify infections early, enabling swift treatment and effective containment strategies. Modern Zika testing methods, such as molecular diagnostics (RT-PCR) and serological tests, provide precise results, allowing healthcare providers to differentiate Zika from other similar infections like dengue and chikungunya. This innovation is particularly crucial for pregnant women, as early detection can significantly reduce the risk of congenital Zika syndrome in newborns.

To Request Sample Report : https://www.globalinsightservices.com/request-sample/?id=GIS32570 &utm_source=SnehaPatil&utm_medium=Article

As outbreaks remain a public health concern, the demand for rapid, cost-effective, and portable testing solutions is driving innovation in the field. Point-of-care devices and advanced laboratory techniques are empowering communities to monitor and manage outbreaks effectively. These advancements in testing are not just about disease control — they represent a proactive step toward safeguarding global health and ensuring that vulnerable populations receive timely care.

#ZikaVirus #VirusTesting #PublicHealth #DiseasePrevention #DiagnosticTools #GlobalHealth #HealthcareInnovation #RT-PCR #SerologicalTesting #VectorBorneDiseases #PregnancyHealth #RapidTesting #PointOfCare #InfectiousDiseases #HealthTech

0 notes

market-insider · 4 months ago

Text

Lyme Disease Testing Market Trends and Analysis: Comprehensive Overview of Market Size, Share, Growth

The global lyme disease testing market size is anticipated to reach USD 18.57 billion by 2030 and is projected to grow at a CAGR of 8.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The primary factors driving this market are the increasing prevalence, supportive government policies regarding healthcare facilities, and the introduction of new diagnostic tests for Lyme disease. In addition, the growing incidence of tick-borne diseases further expands the global market. For instance, in August 2022, the U.S. Fair Health Organization reported that Lyme disease has significantly increased in prevalence over the past 15 years, becoming a growing national concern.

Lyme Disease Testing Market Report Highlights

Based on technology, the other segment led the market with the largest revenue share of 88.6% in 2023. The widespread adoption of these tests, considered the gold standard for testing due to their high specificity and sensitivity, significantly contributed to the growth of this segment

Based on testing, the serological test segment led the market with the largest revenue share of 53.1% in 2023. These tests dominated the market as they are widely available, affordable, established, and reliable in detecting antibodies against Borrelia burgdorferi. This makes them a trusted and accessible option for healthcare providers and patients

Based on sample, the blood segment led the market with the largest revenue share of 62.4% in 2023. This is due to the blood tests, such as ELISA and Western blot, which can effectively detect antibodies against Borrelia burgdorferi, the bacteria causing Lyme disease. Blood samples are also easy to obtain and handle, making them a practical choice for widespread diagnostic use

Based on end use, the hospital segment led the market with the largest revenue share of 58.4% in 2023. Firstly, hospitals can access advanced technology and diagnostic tools, enabling accurate & timely testing. The high hospital patient volume, including those with complex and severe symptoms, necessitates reliable diagnostic services, further driving their market dominance

In January 2024, DiaSorin announced that it submitted the LIAISON LymeDetect test to the U.S. FDA in December 2023. Developed in partnership with QIAGEN, this test detects IgG, IgM, and T-cell mediated responses using QIAGEN’s proprietary QuantiFERON technology, an Interferon-Gamma Release Assay (IGRA). This novel solution will enhance DiaSorin's LIAISON immunodiagnostic offerings in the U.S. market, representing a significant milestone in its collaboration with QIAGEN

For More Details or Sample Copy please visit link @: Lyme Disease Testing Market Report

Growing government initiatives and preventive measures significantly drive the market growth. For instance, in July 2022, an article titled "New laws seek to boost funding of Lyme disease research" highlighted that New York officials have increased funding for Lyme disease and tick-borne illnesses through a new law signed by Governor Kathy Hochul. This bipartisan measure will establish a voluntary tax check-off box to support education, research, and prevention efforts related to the disease in the region. Despite the high incidence of Lyme and tick-borne illnesses, it is believed that the actual number of cases is much higher due to inaccurate diagnostic testing.

Heightened awareness and education are further propelling market growth. Public health campaigns to educate communities about prevention strategies and symptoms have become increasingly prevalent. This growing awareness leads to more individuals seeking medical attention when they exhibit symptoms consistent with the disease, thereby driving demand for reliable testing options. Furthermore, educational initiatives targeting healthcare professionals ensure they remain informed about best practices for diagnosis and treatment.

List of major companies in the Lyme Disease Testing Market

DiaSorin S.p.A

BIOMÉRIEUX

Oxford Immunotec

Bio-Rad Laboratories, Inc.

Thermo Fisher Scientific, Inc.

T2 Biosystems

IGeneX

Gold Standard Diagnostics

ZEUS Scientific

Trinity Biotech

For Customized reports or Special Pricing please visit @: Lyme Disease Testing Market Analysis Report

We have segmented global lyme disease testing market report based on technology, testing, sample, end-use, and region.

#LymeDisease #LymeDiseaseTesting #DiagnosticTesting #InfectiousDisease #HealthDiagnostics #MedicalTesting #VectorBorneDiseases #TickBorneIllness #LymeDiseaseDiagnosis #SerologyTests #PCRTesting #LymeDiseaseAwareness #PointOfCareTesting #LaboratoryDiagnostics #HealthcareMarket #MedicalDevices #ImmunoassayTests #DiagnosticsMarket

0 notes

shubhampawrainfinium · 4 months ago

Text

In the Fight Against Infection: Advanced Testing Technologies

The global infectious disease testing market is poised for substantial growth, propelled by the rising prevalence of infectious diseases, advancements in diagnostic technologies, and increasing awareness regarding early disease detection. According to the report, the market is projected to grow at a compound annual growth rate (CAGR) of around 7.5% over the forecast period of 2022-2028. The revenue generated by the infectious disease testing market was approximately USD 27 billion in 2022 and is expected to reach nearly USD 41 billion by 2028.

What is Infectious Disease Testing?

Infectious disease testing encompasses a range of diagnostic tests designed to detect pathogens, including bacteria, viruses, fungi, and parasites, that cause infectious diseases. These tests can be performed in various settings, including laboratories, clinics, and hospitals, and they include techniques such as PCR (polymerase chain reaction), serology, antigen tests, and culture methods. Early detection and accurate diagnosis are crucial for effective treatment and containment of infectious diseases.

Get Sample pages of Report: https://www.infiniumglobalresearch.com/reports/sample-request/40131

Market Dynamics and Growth Drivers

Several key factors are driving the growth of the global infectious disease testing market:

Increasing Incidence of Infectious Diseases: The rise in infectious diseases, including viral outbreaks (e.g., COVID-19, influenza) and bacterial infections, is driving the demand for testing solutions. Global health threats and pandemics have underscored the importance of rapid and accurate diagnostic testing.

Technological Advancements: Innovations in diagnostic technologies, including the development of point-of-care testing, molecular diagnostics, and rapid testing methods, are enhancing the efficiency and accuracy of infectious disease testing. These advancements enable timely diagnosis and treatment, contributing to improved patient outcomes.

Growing Awareness and Preventive Healthcare: There is a growing emphasis on preventive healthcare and early disease detection. Increasing public awareness about infectious diseases and the importance of testing is driving demand for diagnostic solutions. Public health initiatives aimed at controlling outbreaks also contribute to the market's growth.

Expansion of Healthcare Infrastructure: The expansion of healthcare infrastructure, especially in developing regions, is facilitating access to diagnostic testing services. Increased investments in healthcare facilities and laboratories are essential for managing infectious diseases and enhancing diagnostic capabilities.

Regional Analysis

North America: North America holds a significant share of the infectious disease testing market, driven by advanced healthcare infrastructure, high adoption of innovative diagnostic technologies, and substantial government investments in public health initiatives. The U.S. is a key market, with ongoing efforts to enhance disease surveillance and control.

Europe: Europe is a major market for infectious disease testing, supported by robust healthcare systems, high disease awareness, and significant investments in research and development. Countries such as Germany, the U.K., and France are at the forefront of adopting advanced diagnostic solutions.

Asia-Pacific: The Asia-Pacific region is witnessing rapid growth in the infectious disease testing market due to increasing healthcare expenditure, rising population awareness, and expanding healthcare infrastructure. Emerging economies like China and India are focusing on improving their healthcare systems and diagnostic capabilities.

Latin America and Middle East & Africa: These regions are experiencing gradual growth in the infectious disease testing market, driven by rising investments in healthcare infrastructure, increasing disease burden, and improving access to diagnostic services.

Competitive Landscape

The infectious disease testing market is competitive, with several key players providing innovative solutions. Key players include:

Abbott Laboratories: A leading player in the diagnostics market, known for its extensive range of infectious disease testing solutions.

Roche Diagnostics: Offers advanced diagnostic tests and platforms for the detection of infectious diseases, including molecular and serological tests.

Siemens Healthineers: Provides a wide array of infectious disease testing solutions, including point-of-care and laboratory tests.

Thermo Fisher Scientific: Known for its innovative diagnostic technologies and comprehensive product portfolio in infectious disease testing.

BD (Becton, Dickinson and Company): A major player in the diagnostics field, offering a range of solutions for infectious disease detection and monitoring.

Report Overview : https://www.infiniumglobalresearch.com/reports/global-infectious-disease-testing-market

Challenges and Opportunities

The infectious disease testing market faces challenges, including regulatory hurdles, high costs associated with advanced testing technologies, and the need for continuous innovation to keep pace with emerging infectious diseases. Additionally, disparities in healthcare access can hinder testing in low-resource settings.

However, there are significant opportunities for growth. The increasing focus on personalized medicine, advancements in genomic testing, and the rise of telehealth solutions present avenues for market expansion. Companies that invest in research and development, cost-effective testing solutions, and partnerships with healthcare providers are well-positioned to capitalize on the growing demand for infectious disease testing.

Conclusion

The global infectious disease testing market is set for substantial growth, driven by rising infectious disease prevalence, technological advancements, and increasing awareness of the importance of early diagnosis. With revenue expected to reach nearly USD 41 billion by 2028, the market presents significant opportunities for innovation and investment. As the healthcare landscape continues to evolve, infectious disease testing will play a crucial role in enhancing public health and improving patient outcomes through timely and accurate diagnoses.

Discover More of Our Reports

Hydroponic Fodder Systems Market

Regenerative Agriculture Market

Fromage Frais and Quark Market

Pesticide Residue Testing Market

Cut Flower Packaging Market

Orthopedic Devices Market

Medical Transport Box Market

IoT in Agriculture Market

Hydrogen Fuel Cell Market

Medical Tourism Market

Homogenizers Market

0 notes

gis56 · 4 months ago

Text

"Market Dynamics 2024-2033: The Arbovirus Testing Revolution"

Arbovirus Testing Market : Arbovirus testing has become a critical tool in managing and preventing the spread of mosquito-borne diseases like Zika, dengue, and West Nile virus. With cutting-edge diagnostic methods, healthcare providers can now detect arbovirus infections faster and more accurately, helping public health agencies respond swiftly to outbreaks. These advanced tests, including PCR and serology, allow for early detection and differentiation of multiple viruses, ensuring that patients receive timely treatment and communities can take necessary precautions to minimize transmission risks.

To Request Sample Report : https://www.globalinsightservices.com/request-sample/?id=GIS26941 &utm_source=SnehaPatil&utm_medium=Article

In addition to improving patient outcomes, arbovirus testing is essential for global surveillance efforts. By identifying hotspots and tracking the spread of viruses, testing helps inform vaccination strategies, vector control initiatives, and public health policies. As climate change increases the reach of vector-borne diseases, robust and accessible arbovirus testing will play a pivotal role in safeguarding populations worldwide.

#ArbovirusTesting #PublicHealth #DiseasePrevention #ZikaVirus #DengueFever #WestNileVirus #PCRTesting #Serology #VectorBorneDiseases #InfectiousDiseaseControl #GlobalHealth #EarlyDetection #HealthTech #EpidemicResponse #MosquitoControl

0 notes

deshpandeisha · 4 months ago

Text

Overview of Veterinary Reference Laboratories: Functions and Importance

The veterinary reference laboratory market plays a crucial role in providing accurate and comprehensive diagnostic services for animals. Veterinary reference laboratories are specialized facilities that offer a wide range of diagnostic tests and services to veterinarians, researchers, and livestock producers. These laboratories are equipped with advanced technologies and expert professionals who perform complex tests to identify diseases, monitor animal health, and ensure the quality of animal-derived products.

According to the World Organization for Animal Health (OIE), animal diseases are responsible for significant economic losses and pose risks to human health. The OIE estimates that livestock diseases cause an economic impact of around $300 billion annually. Furthermore, the United States Department of Agriculture (USDA) reports that the global demand for animal products is expected to increase by 70% by 2050, driving the need for robust and reliable diagnostic services to ensure animal health and the quality of food products.

The global veterinary reference laboratory market size is expected to reach USD 10.2 Billion in 2032 and register a revenue CAGR of 9.4% during the forecast period, according to latest analysis by Emergen Research. There are several key drivers contributing to the growth of the veterinary reference laboratory market. Firstly, the increasing prevalence of animal diseases, both infectious and non-infectious, has created a need for accurate and reliable diagnostic services. Veterinary reference laboratories provide specialized testing capabilities, including serology, pathology, microbiology, and molecular diagnostics, which aid in the detection and monitoring of various diseases in animals. Additionally, the growing demand for livestock products and the increasing pet population have resulted in a higher requirement for diagnostic services to ensure the health and well-being of animals.

Get Download Pdf Sample Copy of this Report@ https://www.emergenresearch.com/request-sample/1940

Competitive Terrain:

The global Veterinary Reference Laboratory industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.

The leading market contenders listed in the report are:

IDEXX, VCA Animal Hospitals, GD, Greencross Vets, Zoetis Services LLC, Neogen Corporation, Abbott, Siemens Healthcare GmbH, Kansas State University, LABOKLIN GMBH & CO. KG

Key market aspects studied in the report:

Market Scope: The report explains the scope of various commercial possibilities in the global Veterinary Reference Laboratory market over the upcoming years. The estimated revenue build-up over the forecast years has been included in the report. The report analyzes the key market segments and sub-segments and provides deep insights into the market to assist readers with the formulation of lucrative strategies for business expansion.

Competitive Outlook: The leading companies operating in the Veterinary Reference Laboratory market have been enumerated in this report. This section of the report lays emphasis on the geographical reach and production facilities of these companies. To get ahead of their rivals, the leading players are focusing more on offering products at competitive prices, according to our analysts.

Report Objective: The primary objective of this report is to provide the manufacturers, distributors, suppliers, and buyers engaged in this sector with access to a deeper and improved understanding of the global Veterinary Reference Laboratory market.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now)@ https://www.emergenresearch.com/request-discount/1940

Market Segmentations of the Veterinary Reference Laboratory Market

This market is segmented based on Types, Applications, and Regions. The growth of each segment provides accurate forecasts related to production and sales by Types and Applications, in terms of volume and value for the period between 2022 and 2030. This analysis can help readers looking to expand their business by targeting emerging and niche markets. Market share data is given on both global and regional levels. Regions covered in the report are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Research analysts assess the market positions of the leading competitors and provide competitive analysis for each company. For this study, this report segments the global Veterinary Reference Laboratory market on the basis of product, application, and region:

Segments Covered in this report are:

Technology Outlook (Revenue, USD Billion; 2019–2032)

Clinical Chemistry

Hematology

Immunodiagnostics

ELISA

Lateral Flow Rapid Tests

Others

Molecular Diagnostics

PCR

Microarrays

Others

Application Outlook (Revenue, USD Billion; 2019–2032)

Clinical Pathology

Toxicology

Productivity Testing

Others

Animal Type Outlook (Revenue, USD Billion; 2019–2032)

Production Animals

Companion Animals

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/veterinary-reference-laboratory-market

Major Geographies Analyzed in the Report:

North America (U.S., Canada)

Europe (U.K., Italy, Germany, France, Rest of EU)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

ToC of the report:

Chapter 1: Market overview and scope

Chapter 2: Market outlook

Chapter 3: Impact analysis of COVID-19 pandemic

Chapter 4: Competitive Landscape

Chapter 5: Drivers, Constraints, Opportunities, Limitations

Chapter 6: Key manufacturers of the industry

Chapter 7: Regional analysis

Chapter 8: Market segmentation based on type applications

Chapter 9: Current and Future Trends

Request Customization as per your specific requirement@ https://www.emergenresearch.com/request-for-customization/1940

About Us:

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: [email protected]

Visit for More Insights: https://www.emergenresearch.com/insights

Explore Our Custom Intelligence services | Growth Consulting Services

Trending Titles: Geocell Market | Pancreatic Cancer Treatment Market

Latest Report: Ceramic Tiles Market | Life Science Analytics Market

0 notes

mitalipingale · 6 months ago

Text

https://twikkers.nl/blogs/262948/Serological-Testing-Market-Share-Overview-Competitive-Analysis-and-Forecast-2031

The Serological Testing Market in 2023 is US$ 4.81 billion, and is expected to reach US$ 8.22 billion by 2031 at a CAGR of 6.90%.

#Serological Testing Market #Serological Testing Market Report #Serological Testing Market Research

0 notes

soumyafwr · 1 year ago

Text

Serological Testing Market

#Serological Testing Market scope #Serological Testing Market report #Serological Testing Market research

0 notes

credenceresearchdotblog · 5 months ago

Text

The Yersinia Diagnostics Market is projected to grow from USD 276.5 million in 2023 to an estimated USD 434.09 million by 2032, with a compound annual growth rate (CAGR) of 5.80% from 2024 to 2032. The Yersinia diagnostics market is gaining significant attention as the global healthcare industry sharpens its focus on infectious diseases. Yersinia, a genus of bacteria that includes species like *Yersinia pestis*, *Yersinia enterocolitica*, and *Yersinia pseudotuberculosis*, is known for causing diseases ranging from gastrointestinal infections to the infamous bubonic plague. Advances in diagnostic technologies are enabling more accurate and timely detection of Yersinia infections, leading to improved patient outcomes and public health management.

Browse the full report at https://www.credenceresearch.com/report/yersinia-diagnostics-market

Market Overview

The global Yersinia diagnostics market is poised for growth, driven by factors such as increased awareness of infectious diseases, rising investments in healthcare infrastructure, and the development of advanced diagnostic tools. The growing prevalence of foodborne diseases, especially in regions with poor sanitation and food safety standards, has also highlighted the importance of accurate diagnostics for pathogens like *Yersinia enterocolitica*, which is a leading cause of yersiniosis.

Yersinia diagnostics involve several techniques, including serological tests, polymerase chain reaction (PCR) assays, enzyme-linked immunosorbent assays (ELISA), and culture methods. The rising adoption of molecular diagnostics, which offer higher sensitivity and specificity, is a key driver for the market. Moreover, increased governmental and institutional focus on controlling zoonotic diseases further propels the market's expansion.

Key Market Drivers

1. Increasing Prevalence of Yersinia Infections: Yersiniosis, caused primarily by *Yersinia enterocolitica, is recognized as a significant foodborne illness, particularly in Europe, Japan, and North America. The Centers for Disease Control and Prevention (CDC) reports approximately 117,000 infections annually in the United States alone, with the true number likely higher due to underreporting. Rising awareness of such infections is boosting demand for advanced diagnostic tools.

2. Technological Advancements: The field of molecular diagnostics is advancing rapidly. Techniques such as PCR and next-generation sequencing (NGS) allow for quicker and more precise identification of Yersinia species. These innovations reduce the time to diagnosis, which is critical for timely treatment, especially in the case of *Yersinia pestis*, the causative agent of plague. Rapid diagnostic methods are essential in preventing outbreaks and controlling the spread of this historically devastating disease.

3. Rising Government Initiatives and Research Funding: Governments worldwide are increasing investments in healthcare infrastructure and infectious disease control programs, which directly impact the Yersinia diagnostics market. For example, research grants for the development of rapid diagnostics for biothreat agents like *Yersinia pestis* are becoming more common, particularly in the U.S. and European Union. Enhanced public health surveillance systems and preparedness programs further support market growth.

4. Focus on Food Safety: As Yersinia enterocolitica is primarily transmitted through contaminated food, particularly pork products, there is a growing focus on improving food safety standards. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Food Safety Authority (EFSA) are implementing stricter guidelines for detecting and managing foodborne pathogens. The need for reliable diagnostic tools in food testing laboratories has, in turn, bolstered the Yersinia diagnostics market.

Market Challenges

Despite the promising growth trajectory, the Yersinia diagnostics market faces certain challenges. The high cost of advanced diagnostic technologies, particularly molecular tests, remains a barrier to widespread adoption in developing regions. Additionally, the limited availability of diagnostic laboratories and skilled personnel in low-resource settings poses a challenge for global market expansion. The complex nature of Yersinia infections, which often present with nonspecific symptoms, can also delay diagnosis and treatment.

Regional Insights

The Yersinia diagnostics market is regionally diverse, with significant demand in North America, Europe, and Asia-Pacific. North America holds the largest market share due to its well-established healthcare infrastructure, advanced diagnostic capabilities, and strong governmental support for disease surveillance. Europe follows closely, with the European Centre for Disease Prevention and Control (ECDC) actively monitoring foodborne illnesses, including yersiniosis.

In the Asia-Pacific region, rising healthcare expenditure and growing awareness of foodborne diseases are driving the market. Countries like Japan and China are emerging as key players due to increasing investments in diagnostic technologies and public health initiatives. In contrast, Latin America and Africa, while witnessing growing demand for diagnostics, face challenges related to healthcare accessibility and funding.

Competitive Landscape

The Yersinia diagnostics market is characterized by the presence of several key players, including Thermo Fisher Scientific, Bio-Rad Laboratories, Abbott Laboratories, and Becton, Dickinson and Company. These companies are focusing on product innovation, collaborations, and strategic acquisitions to strengthen their market position. For instance, the development of point-of-care diagnostics and portable testing devices is a notable trend aimed at increasing accessibility in remote and underserved areas.

Key players

Thermo Fisher Scientific

Merck KGaA

BD (Becton, Dickinson and Company)

bioMérieux SA

Bio-Rad Laboratories Inc.

ELITechGroup Inc.

GlaxoSmithKline plc.

Lonza

PerkinElmer Inc.

QIAGEN

Hoffmann-La Roche Ltd

Siemens

SeraCare Life Sciences Inc.

Abbott

Gen-Probe

Hologic Inc.

Danaher Corporation

Robert Bosch GmbH

Segments

Based on Test Type

Stool Culture

ELISA

Radioimmunoassay

Tube Agglutination

CT Scan

Ultrasonography

Colonoscopy

Based on Technology

DNA Probes

Immunoassay

Monoclonal Antibodies

PCR

Based on End User

Hospital Laboratories

Public Health Laboratories

Commercial Laboratories

Based on Region

North America

Canada

Mexico

Europe

Germany

France

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Browse the full report at https://www.credenceresearch.com/report/yersinia-diagnostics-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: [email protected]

Website: www.credenceresearch.com

0 notes

industrynewsupdates · 5 months ago

Text

Blood Screening Market Key Companies, Growth and Forecast Report, 2030

The global blood screening market size was valued at USD 2.76 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 11.7% from 2023 to 2030.

Blood screening is a process in which donated blood is screened for infectious diseases such as HBV, HCV, HIV1, and HIV2. The high growth of this market is attributed to rising blood donations, an increase in the incidence of infectious diseases, and government initiatives. According to World Health Organization (WHO), 118.54 million blood donations are collected yearly. In the U.S., 6.8 million individuals donate blood annually, and 13.6 million units of red blood cells and whole blood are collected annually.

The market is primarily driven by the rise in the rate of disorders such as HIV, diphtheria, measles and chronic diseases such as hemophilia, cancer, and other blood-related disorders. Blood-based diagnostics are used to diagnose a wide range of diseases, including infectious diseases, cancer, and cardiovascular diseases. Serology tests detect the presence of antibodies to a specific disease-causing organism. These tests diagnose various infectious diseases, including HIV, hepatitis B, and syphilis. Molecular tests detect the presence of DNA or RNA from a specific disease-causing organism. These tests are more sensitive than serology tests and can be used to diagnose diseases at an earlier stage. Biochemical tests measure the levels of certain substances in the blood. These tests can diagnose a wide range of diseases, including diabetes, kidney disease, and liver disease.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

Blood Screening Market Report Highlights

• The reagent segment accounted for the largest revenue share of around 73.0% in 2022 and is expected to grow at the fastest CAGR of 12.0% over the forecast period.

• North America dominated the market and accounted for the largest revenue share of 39.0% in 2022 owing to the presence of key industry players, increased adoption of the blood screening process, stringent FDA regulations for transfusion, rising infectious disease prevalence, and greater patient affordability are responsible for maintaining its position during the forecast period.

• Asia Pacific is expected to grow at the fastest CAGR of 13.5% over the forecast period owing to increasing awareness about blood donation, rising patient affordability, and the focus of key industry players on emerging countries in the region.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global sentinel node biopsy market size was estimated at USD 717.8 million in 2023 and is projected to grow at a CAGR of 7.0% from 2024 to 2030.

• The global market for endoscopy operative devices reached a value of USD 10.34 billion in 2023 and is projected to grow at a CAGR of 5.3% from 2024 to 2030.

Blood Screening Market Segmentation

Grand View Research has segmented the blood screening market by product, technology, and region:

Blood Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Nucleic Acid Amplification Test (NAT)

• ELISA

• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

• Next Generation Sequencing

• Western Blotting

Blood Screening Product Outlook (Revenue, USD Million, 2018 - 2030)

• Reagent

• Instrument

Blood Screening Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Sweden

o Norway

o Denmark

• Asia Pacific

o Japan

o China

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa

o Saudi Arabia

o South Africa

o UAE

o Kuwait

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.

#Blood Screening Market #Blood Screening Market size #Blood Screening Market share #Blood Screening Market analysis #Blood Screening Industry

0 notes